Hydrochlorothiazide, Captopril | Caposide tablets 50 mg + 25 mg 28 pcs.

Latin name

Capozid

Release form

Tablets.

Packing

28 pcs

Indications

Arterial hypertension (for patients who are shown combination therapy)

Contraindications

Hypersensitivity to captopril, any other component of the drug or other ACE inhibitors, thiazide diuretics and other sulfanilamide derivatives (possible cross-allergic reactions)

angioedema, hereditary or idiopathic, including ,

mitral stenosis

hypertrophic obstructive cardiomyopathy

bilateral renal artery stenosis, single-kidney renal artery stenosis

kidney transplantation (history)

chronic heart failure

cardiogenic shock, acute liver disease, acute liver disease (serum creatinine more than 1.8 mg / 100 ml or creatinine clearance less than 20-30 ml / min, anuria)

primary hyperaldosteronism

simultaneous use with aliskiren and aliskirensoderzhaschimi drugs in patients with diabetes or impaired renal function (GFR of less than 60 ml / min),

pregnancy,

during breastfeeding,

age 18 years (effectiveness and safety installed)

lactose intolerance, lactase deficiency and glucose-galactose malabsorption syndrome.

With caution

• Impaired liver function, progressive liver disease,

• moderate renal failure (creatinine clearance 30-60 ml / min),

• proteinuria (more than 1 g / day),

• hypokalemia (not corrected by drugs)

• hyponatremia,

• hypovolemia,

• hypercalcemia,

• gout, hyperuricemia,

• systemic diseases of connective tissue and other autoimmune diseases (including systemic lupus erythematosus, scleroderma, periarteritis nodosa • older soylkp 65 years old),

• simultaneous administration of drugs that suppress the body's defenses (glucocorticosteroids, cytostatics, immunosuppressants), allopurinol, procainamide

• surgery / general anesthesia, use in patients of the Negroid race, hemodialysis using high-strength membranes (for example, AN69®), desensitizing therapy, simultaneous use of potassium-sparing diuretics, potassium preparations, potassium substitutes and lithium, acute myopia and secondary closed angle.

Pregnancy and lactation

Not recommended.

Composition

One tablet contains:

active ingredients: captopril in terms of 100% substance - 50 mg, hydrochlorothiazide in terms of 100% substance - 25 mg

excipients: microcrystalline cellulose - 118.5 mg, pregelatinized starch ( - 30 mg stearic acid - 6 mg, magnesium stearate - 0.3 mg, lactose monohydrate - 70.2 mg.

Dosage and administration

Caposide is taken orally, regardless of food intake. Start with 1/2 table., Increasing the dose to 1 table. 1 time per day (maintenance dose).

Side effects of

From the cardiovascular system: flushing of the face, fever, dizziness: headache tachycardia palpitations swelling of the legs, marked decrease in blood pressure (including orthostatic) with symptoms of dizziness, feeling weak, in rare cases - fainting, tachycardia, palpitations with a sharp or prolonged excessive decrease in blood pressure - a transient disturbance of cerebral circulation, stroke myocardial infarction.

On the part of water-electrolyte metabolism: disturbances in the water-electrolyte balance: dry mouth, thirst, feeling tired, depression, drowsiness, weakness. In rare cases, a decrease in the formation of tear fluid.

From the respiratory system: bronchospasm, dry cough in rare cases - respiratory failure, sinusitis, rhinitis, laryngitis.

Allergic reactions: angioedema of the larynx, pharynx and / or tongue, allergic reactions (up to the development of pulmonary edema), skin rash (exanthema, in rare cases, urticaria).

Dermatological reactions: exfoliative dermatitis, erythema multiforme exudative (including Stevens-Johnson syndrome), as well as toxic epidermal necrolysis (Lyell's syndrome). These changes in the skin can be accompanied by a rise in body temperature, pain in the muscles and joints, the development of vasculitis. In some cases, skin changes resembling psoriasis, photosensitivity, hair loss, disorders of the nails (onycholysis).

From the digestive system: nausea, vomiting, constipation or diarrhea, discomfort in the stomach, abdominal pain, decreased appetite, acute cholecystitis (against cholelithiasis), hemorrhagic pancreatitis, hepatitis, cholestatic jaundice, increased activity of liver enzymes, hyperbilirubinemia. With prolonged use: gingival hyperplasia, asthenia, taste change, impaired renal function, nephritis. From the central and peripheral nervous system: headache, feeling tired, in rare cases - depression, depression, sleep disturbances, decreased potency, cramps disturbed balance, dizziness, tinnitus, blurred vision, progression of myopia, tremor, paresthesia taste disturbances.

From the hemopoietic system: anemia, decreased hematocrit, thrombocytopenia, leukopenia, neutropenia (up to the development of pancytopenia and agranulocytosis - especially with the simultaneous administration of allopurinol, procainamide, as well as immunosuppressants), eosinophilia, increased titer of antinuclear antibodies.

From the urinary system: proteinuria in rare cases, especially in patients with renal failure, there may be an increase in serum concentrations of urea, creatinine and potassium ions (the risk of hyperkalemia is also increased in patients with diabetes mellitus), as well as hyponatremia.

From the side of metabolism: hyperlipidemia, hyperglycemia, hyperuricemia (up to exacerbation of gout).

Drug Interaction

In vivo studies aimed at studying interaction with other drugs have not been conducted.

Based on in vitro data, we can assume that there is no inhibition of cytochrome P450 isoenzyme activity in vivo.

In vitro data have shown the inhibition of betahistine metabolism by drugs that inhibit MAO, including MA subtype B (eg, selegiline). Caution should be exercised when administering betahistine and MAO inhibitors (including MAO-B).

Betahistine is an analogue of histamine, there is a risk of pharmacokinetic interaction with drugs whose metabolism occurs in the liver, such as methotrexate and lithium preparations.

Aceclofenac is almost completely bound to plasma proteins, and therefore it is necessary to consider the possibility of substitution by other drugs, which are highly bound to plasma proteins.

In the absence of pharmacokinetic interaction studies, the following information is based on information obtained from other NSAIDs.

The following combinations of

NSAIDs should suppress the tubular secretion of methotrexate, and metabolic interactions may also be observed leading to a decrease in methotrexate clearance. Therefore, NSAIDs should always be avoided during treatment with high doses of methotrexate.

Some NSAIDs suppress the excretion of lithium by the kidneys, Concomitant treatment with potassium-sparing diuretics may be associated with an increase in serum potassium, so control of potassium in the blood is necessary.

NSAIDs may also reduce the effects of some antihypertensive drugs. ACE inhibitors or angiotensin II receptor antagonists in combination with NSAIDs can lead to kidney failure. The risk of developing acute renal failure, which is usually reversible, may be increased in some patients with impaired renal function, such as the elderly or patients with fluid deficiency. Therefore, the combination of these drugs with NSAIDs should be used with caution, patients should receive sufficient amount of fluid with food, and renal function should be monitored.When used in combination with other cytostatics and interferon-alpha, an increase in both the antitumor effect and the toxicity of fluorouracil may also be observed. With prolonged co-administration with mitomycin C, hemolytic uremic syndrome has been observed.

When co-administered with sorivudine, marked leukopenia was observed, in some cases leading to death.

Fluorouracil should not be used after and in combination with aminophenazone, phenylbutazone and sulfonamide therapy.

Chlordiazopoxide, disulfiram, griseofulvin and isoniazid can enhance the activity of 5 fluorouracil. Fluorouracil may reduce the immunological response to vaccination. When co-administered with a live vaccine, severe antigenic reactions may develop.

The development of erythrocyte hemolysis is possible with the administration of methyldopa.

Colestyramine decreases the absorption of Caposide.

Salt and non-steroidal anti-inflammatory drugs (NSAIDs) reduce the severity of hypotensive action.

Potassium salts, potassium-sparing diuretics and heparin contribute to the development of hyperkalemia.

The use of Kaposide on the background of hemodialysis using certain high-permeability dialysis membranes (eg, polyacrylonitrile-methylsulfonate membranes) increases the risk of allergic reactions (anaphylactoid reactions).

Overdose

Increased severity of side effects.

Treatment: symptomatic therapy.

Storage conditions

The drug should be stored in a dry, dark place, out of the reach of children, at a temperature not exceeding 20 РC.

Expiration

3 years.

dosage form

dosage form

tablets

Akrikhin HFK AO, Russia